# (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

> **NCT04411472** · PHASE3 · TERMINATED · sponsor: **AM-Pharma** · enrollment: 676 (actual)

## Conditions studied

- Acute Kidney Injury Due to Sepsis

## Interventions

- **BIOLOGICAL:** Recombinant human alkaline phosphatase
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04411472
- **Lead sponsor:** AM-Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-02
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 676 (ACTUAL)
- **Why stopped:** The Data Monitoring Committee (DMC) concluded that the pre-specified futility threshold was met and that there was no safety concern.
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04411472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04411472, "(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04411472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*